Shots:

• Immatics to receive $150M up front, $770M in development, regulatory & commercial milestone along with royalties. The agreement built on Immatics’ capabilities to identify novel targets & develop high-affinity, target-specific TCRs
• Immatics gets the option to co-fund US development in return for US royalty & co-promote IMA401 in the US. In preclinical POC studies, IMA401 showed anti-tumor activity with complete remissions in multiple in vivo tumor models including patient-derived xenograft models
• In Nov 2021, Immatics filed a CTA with PEI for the development of IMA401 which is expected to be initiated in H1’22. In 2019, Immatics & Celgene collaborated to develop  adoptive cell therapies

Ref: BMS | Image: Bristol Myers Squibb